Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic Model

• Main Authors: Jurij Aguiar Zdovc (Author), Jurij Hanžel (Author), Tina Kurent (Author), Nejc Sever (Author), Matic Koželj (Author), Nataša Smrekar (Author), Gregor Novak (Author), Borut Štabuc (Author), Erwin Dreesen (Author), Debby Thomas (Author), Tomaž Vovk (Author), Barbara Ostanek (Author), David Drobne (Author), Iztok Grabnar (Author)
• Format: Book
• Published: MDPI AG, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Ustekinumab is a monoclonal antibody used in Crohn's disease (CD). Dose optimization in case of non-response and the role of pharmacokinetic-pharmacodynamic (PK-PD) monitoring remain unresolved dilemmas in clinical practice. We aimed to develop a population PK-PD model for ustekinumab in CD and...